Main points:
Review of sector Market:
This week (4.25 ~ 4.29), Shenwan beauty care sector rose + 0.06%. Shanghai Composite Index and gem index were – 1.29% and + 0.98% respectively. Shenwan beauty care sector outperformed Shanghai Composite Index by 1.35pct and underperformed gem index by 0.92pct.
Wind medical beauty and cosmetics index: this week, CSI 300 index + 0.07%, wind medical beauty index – 4.97%, underperforming CSI 300 market by 5.04pct; The wind cosmetics index was – 2.88%, underperforming the CSI 300 market by 2.95pct.
Industry highlights:
(1) the filing of cosmetics raw materials by the State Food and Drug Administration shows that the new raw materials of hydrolyzed zinc hyaluronate (filing No.: Guozhuang Yuanbei Zi 20220008) have been successfully filed. Hydrolyzed zinc hyaluronate has the effects of both HA and zinc, has the functions of moisturizing and protecting skin, and can be used in facial mask, essence, cream, toothpaste, mouthwash, shampoo and other personal care products. (State Food and Drug Administration)
(2) affected by the repeated global epidemic, the energy crisis and the obstruction of international shipping, the price of palm oil raw materials has repeatedly hit new highs since last year, which has also pushed up the cost pressure of relevant enterprises. In response to the supply shortage, Indonesia, the world’s largest producer and exporter of palm oil, will suspend the export of palm oil and related raw materials on April 28. (First Finance)
Company announcement:
Yunnan Botanee Bio-Technology Group Co.Ltd(300957) : release the report for the first quarter of 2022. In the first quarter of 2022, the company achieved an operating revenue of 810 million yuan (YoY + 59.3%), a net profit attributable to the parent company of 150 million yuan (YoY + 85.7%), and a basic earnings per share of 0.34 yuan / share.
Shanghai Jahwa United Co.Ltd(600315) : release the report for the first quarter of 2022. In the first quarter of 2022, the company achieved operating revenue of 2.12 billion yuan (YoY + 0.11%), net profit attributable to the parent company of 200 million yuan (YoY + 17.81%), and basic earnings per share of 0.30 yuan / share.
Bloomage Biotechnology Corporation Limited(688363) : release the report for the first quarter of 2022. In the first quarter of 2022, the company achieved an operating revenue of 1.25 billion yuan (YoY + 61.6%), a net profit attributable to the parent company of 200 million yuan (YoY + 31.1%), and a basic earnings per share of 0.42 yuan / share.
Imeik Technology Development Co.Ltd(300896) : released the report for the first quarter of 2022. In 2022, Q1 company achieved a revenue of 430 million yuan (YoY + 66.07%), a net profit attributable to the parent company of 280 million yuan (YoY + 64.03%), and a basic earnings per share of 1.29 yuan / share.
Lancy Co.Ltd(002612) : released the report for the first quarter of 2022. In the first quarter of 2022, the company realized an operating revenue of 890 million yuan (YoY + 0.3%), a net profit attributable to the parent company of -2.422 million yuan (yoy-106.4%), and a basic earnings per share of -0.005 yuan / share.
Huadong Medicine Co.Ltd(000963) : release the report for the first quarter of 2022. In the first quarter of 2022, the company achieved an operating revenue of 8.933 billion yuan (+ 0.4%); The net profit attributable to the parent company was 704 million yuan (- 7.12%); The basic earnings per share is 0.4025 yuan.
Investment advice
(1) cosmetics industry: after the disclosure of Q1 performance of listed companies, the head cosmetics brands dominated by online sales continued to increase rapidly, such as Yunnan Botanee Bio-Technology Group Co.Ltd(300957) , Bloomage Biotechnology Corporation Limited(688363) net profit attributable to parent companies, with growth rates of 85.7% and 31.1% respectively. In the context of stricter supervision of the cosmetics industry, strong products + strong brands bring the possibility of breaking the brand circle, and continue to pay attention to the head cosmetics brands with strong R & D ability and brand strength. Attention: [ Yunnan Botanee Bio-Technology Group Co.Ltd(300957) ] subdivide the leader in the field of sensitive muscle skin care; [ Proya Cosmetics Co.Ltd(603605) ] diversified high-quality brands; [ Shanghai Jahwa United Co.Ltd(600315) ] multi category development and continuous innovation to create new items; [ Guangdong Marubi Biotechnology Co.Ltd(603983) ] focuses on medium and high-end, with rich marketing and distribution channels; [ Syoung Group Co.Ltd(300740) ] strong operation capacity and gradual improvement of category structure.
(2) medical and beauty industry: the performance of medical and beauty industry has been differentiated. The net profit of Imeik Technology Development Co.Ltd(300896) parent company of upstream products increased by 64%, showing a bright performance. The performance of downstream institutions has shrunk due to the repeated epidemic and the impact of their main business. The demand side of the medical beauty industry continues to expand, the supply side products are more diversified, and the policy side strengthens the supervision of medical beauty institutions and medical beauty products. We are optimistic about upstream medical and American enterprises with class III medical device certificate and perfect product matrix layout and downstream medical institutions with long-term standardized operation. Attention: [ Bloomage Biotechnology Corporation Limited(688363) ] local hyaluronic acid raw material leader; [ Imeik Technology Development Co.Ltd(300896) ] Tongyan needle is heavily listed, and differentiation meets higher demand; [ Huadong Medicine Co.Ltd(000963) ] overall layout of medical beauty business; [ Shanghai Haohai Biological Technology Co.Ltd(688366) ] integration of R & D, production and sales; [Sihuan medicine] botulinum toxin + double antibody go hand in hand; Pay attention to Lancy Co.Ltd(002612) etc. of the layout of downstream medical and aesthetic institutions.
Risk tips
The impact of repeated outbreaks; The risk of intensified industry competition; Uncertainty of industrial regulatory policies; Macroeconomic fluctuations, etc.
